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Abstract
Background: The nuclear receptors peroxisome proliferator-activated receptor g (PPARg) and peroxisome
proliferator-activated receptor δ (PPARδ) play central roles in regulating metabolism in adipose tissue, as well as
being targets for the treatment of insulin resistance. While the role of PPARg in regulating insulin sensitivity has
been well defined, research into PPARδ has been limited until recently due to a scarcity of selective PPARδ
agonists.
Results: The metabolic effects of PPARg and PPARδ activation have been examined in vivo in white adipose tissue
from ob/ob mice and in vitro in cultured 3T3-L1 adipocytes using
1H nuclear magnetic resonance spectroscopy and
mass spectrometry metabolomics to understand the receptors’ contrasting roles. These steady state measurements
were supplemented with
13C-stable isotope substrate labeling to assess fluxes, in addition to respirometry and
transcriptomic microarray analysis. The metabolic effects of the receptors were readily distinguished, with PPARg
activation characterized by increased fat storage, synthesis and elongation, while PPARδ activation caused increased
fatty acid b-oxidation, tricarboxylic acid cycle rate and oxidation of extracellular branch chain amino acids.
Stimulated glycolysis and increased fatty acid desaturation were common pathways for the agonists.
Conclusions: PPARg and PPARδ restore insulin sensitivity through varying mechanisms. PPARδ activation increases
total oxidative metabolism in white adipose tissue, a tissue not traditionally thought of as oxidative. However, the
increased metabolism of branch chain amino acids may provide a mechanism for muscle atrophy, which has been
linked to activation of this nuclear receptor. PPARδ has a role as an anti-obesity target and as an anti-diabetic, and
hence may target both the cause and consequences of dyslipidemia.
Background
The World Health Organization estimates over 180 mil-
lion people worldwide suffer from type 2 diabetes melli-
tus (T2DM). The incidence of obesity, a major risk
factor for the development of T2DM, is also increasing
globally. While a number of anti-diabetic treatments
have been produced, they rarely address the related
obese state and consequently fail to confront this under-
lying risk factor. Therefore, it becomes imperative that
new treatment approaches with both anti-diabetic and
anti-obesity properties are found.
The peroxisome proliferator-activated receptors
(PPARs) are ligand activatedt r a n s c r i p t i o nf a c t o r s ,
belonging to the nuclear receptor superfamily, that con-
trol the expression of genes involved in organogenesis,
inflammation, cell differentiation, proliferation, and lipid
and carbohydrate metabolism [1]. Activation of the
PPARs by their selective ligands results in heterodimeri-
zation of the receptor with the 9-cis-retinoic acid recep-
tor. The PPARs can then bind to specific sequences in
their target genes known as peroxisome proliferator
response elements [2].
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PPARg and PPARδ, with each demonstrating a particu-
lar tissue distribution and ligand specificity [3]. PPARa
is primarily expressed in heart, liver, macrophages and
intestines, and is activated by polyunsaturated fatty acids
and leukotriene B4 [4]. PPARg is principally expressed
in adipocytes but is also found in a range of tissues,
including the placenta. The receptor has a key role in
adipocyte differentiation and lipid storage; it is activated
by polyunsaturated fatty acids and 15d-prostaglandin J2
[5]. PPARδ is expressed almost ubiquitously, though
some tissues express higher concentrations of the
mRNA, including the brain, skin, liver, skeletal muscle
and adipose tissue [6,7]. In recent studies, the vitamin A
metabolite retinoic acid has been identified as a physio-
logical ligand for the PPARδ nuclear receptor, acting to
control cell survival [8].
The PPARs have already yielded viable targets for the
treatment of T2DM and dyslipidemia; thiazolidine-
diones, PPARg agonists, are currently used in the clinic
for the treatment of T2DM; and fibrates, PPARa ago-
nists, are routinely used to treat dyslipidemia. Treatment
with thiazolodinediones results in the recruitment of
new metabolically active adipocytes, causing an increase
in lipid storage capacity and normalization of adipocyto-
kine levels [9].
A pharmacological agonist for PPARδ is yet to make it
into the clinic and the receptor remains to be fully func-
tionally defined. However, the development of a number
of high affinity synthetic ligands for PPARδ has shown
the receptor holds considerable promise for the treat-
ment of T2DM, the metabolic syndrome, dyslipidemia
and obesity. Insulin-resistant obese rhesus monkeys
treated with the selective PPARδ agonist GW501516
demonstrated significant increases in high-density lipo-
protein cholesterol with concomitant decreases in tria-
cylglycerols (TAGs) and low-density lipoprotein
cholesterol [10]. PPARδ activation has also shown effi-
cacy in reducing adiposity by decreasing intracellular tri-
glyceride accumulation in mouse brown adipose tissue
and liver [11].
Investigation into the function of PPARδ in white adi-
pose tissue has demonstrated that the receptor has an
important role in the regulation of metabolism. Tissue-
specific over-expression of PPARδ in the white adipose
tissue of transgenic mice resulted in a decrease in body
weight, adipocyte triglyceride accumulation, circulating
free fatty acids and circulating triglyceride [11]. The
same transgenic mice were also protected against weight
gain, adipocyte hypertrophy, hypertriglyceridemia, and
steatosis. PPARδ activation also leads to elevated expres-
sion of uncoupling protein-1 in white adipose tissue [11].
In order to contrast the roles of PPARg and PPARδ in
regulating metabolism in white adipose tissue, we have
performed a metabolomics study using both in vivo ana-
lysis in the ob/ob mouse and in vitro analysis using the
murine 3T3-L1 adipocyte cell line. The ob/ob mouse
was used to investigate the influence of PPAR activation
on adipose tissue metabolism in a model of insulin
resistance and obesity. The ob/ob mouse model is
robust, well characterized and used extensively to study
T2DM and its therapies; however, it is worthy of note
that it is a monogenic paradigm of leptin deletion,
whereas T2DM is a polygenic disorder.
A synthetic, high affinity pharmacological agonist,
GW610742, was used to activate PPARδ in both the
mice and the adipocyte cell line (GW610742 EC50 for
murine PPARδ is 28 nM compared to 8,900 nM for
PPARa and > 10,000 nM for PPARg)[ 1 2 ]a n dc o n -
trasted with a well defined PPARg agonist (GW347845).
Steady state concentrations were assessed in vivo and in
vitro using a combination of mass spectrometry (MS)
and
1H nuclear magnetic resonance (
1H NMR) spectro-
scopy in conjunction with multivariate statistics to
probe the metabolic phenotypes resulting from activa-
tion of the two nuclear receptors. To unambiguously
define the mechanisms by which PPARδ and PPARg
alter the metabolism of adipose tissue, this was further
characterized by
13C-stable isotope substrate labeling
studies using 1-
13C glucose and U-
13C palmitate,
respirometric analysis using a Clark-type oxygen elec-
trode and transcriptomic microarray analysis.
It was found that PPARδ activation was characterized
not only by increased fatty acid oxidative metabolism as
previously observed but also by increased glucose and
amino acid oxidation. In contrast, activation of PPARg
was associated with fatty acid synthesis and sequestra-
tion of fats. This implicates PPARδ as a control for glo-
bal oxidative energy metabolism and suggests a
mechanism by which activation of the nuclear receptor,
in part, brings about its anti-diabetic and anti-obesity
properties by simultaneously reducing the quantity of
triglycerides and glucose in white adipose tissue and sys-
temic metabolism as a whole. However, this metabolic
systems biology approach also suggests that increased
demand for branched chain amino acids (BCAAs) in
adipose tissue may explain why the wider metabolic
effects of PPARδ activation may cause muscle atrophy.
Results
Metabolomic analysis of adipose tissue from ob/ob mice
treated with the PPAR agonists
A combination of gas chromatography (GC)-MS and
direct infusion (DI)-MS combined with multivariate pat-
tern recognition was used to profile metabolism within
the white adipose tissue of ob/ob mice treated with
either GW610742 (a selective PPARδ agonist),
GW347845 (a selective PPARg agonist) or a vehicle
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Page 2 of 19control. These analytical approaches provided coverage
of total fatty acids and intact lipids and free fatty acids,
respectively. The various spectra and chromatograms
were interrogated using multivariate statistics comparing
the dosed groups with the vehicle control.
Both PPARδ and PPARg agonists induced large
changes in the total fatty acid profile of white adipose
tissue as measured by GC-MS of the fatty acid methyl
esters and subsequent multivariate analysis (Figure 1a-
c). Treatment with the PPARδ agonist induced decreases
in the medium-chain fatty acids, while the concentration
of the shorter chain fatty acids increased (Figure 1d).
This was contrasted by the effect of PPARg where the
most profound change was an increase in activity of Δ-9
desaturase, increasing the concentrations of desaturated
fatty acids, as well as an increase in the long chain fatty
acid arachidate C20:0.
Analysis of the DI-MS negative mode ionization data
of the organic phase was used to analyze changes in free
fatty acids and a number of classes of intact lipids, with
this approach distinguishing both adipose tissue from
ob/ob mice treated with either of the agonists (Figure
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Figure 1 Metabolomic investigation of PPARδ and PPARg activation in white adipose tissue from ob/ob mice. (a) Chromatogram of GC-
MS analysis of the total fatty acid content of white adipose tissue from an ob/ob mouse treated with the PPARδ agonist. Key metabolites are
labeled. (b) Partial least squares-discriminant analysis (PLS-DA) of the GC-MS chromatograms from white adipose tissue from control animals
(filled squares; n = 8) or those treated with a PPARδ (filled circles; n =8 )( R
2(X) = 32%, Q
2 = 69%). (c) PLS-DA of the GC-MS chromatograms from
white adipose tissue from control animals (filled squares; n = 8) or those treated with the PPARg agonist (diamonds; n =8 )( R
2(X) = 32%, Q
2 =
74%). (d) Box whisker plots of key metabolic changes in total fatty acids in white adipose tissue following treatment with either the PPARδ
agonist (n = 8) or PPARg agonist (n = 8). Significant differences were measured by ANOVA followed by a Tukey post-hoc test. *P < 0.05; **P <
0.01; ***P < 0.005. (e) Plot of PLS-DA scores showing the clustering of DI-MS negative ionization mode mass spectra run in triplicate from the
organic phase of white adipose extracts from ob/ob mice treated with a PPARδ agonist compared with control animals: PPARδ agonist-treated
(filled circles; n = 8), control (filled squares; n =8 )( R
2(X) = 72%, Q
2 = 58%). (f) Plot of PLS-DA scores showing the clustering of DI-MS positive
ionization mode mass spectra run in triplicate from the organic phase of white adipose extracts from ob/ob mice treated with a PPARg agonist
compared with control animals: PPARg agonist-treated (diamonds; n = 8), control (filled squares; n =8 )( R
2 = 89%, Q
2 = 95%). (g) Key metabolic
changes detected by liquid chromatography-MS in blood serum from animals treated with either a PPARδ agonist (n = 8) or PPARg agonist (n =
8) compared with wild-type controls (n = 8). The metabolite changes demonstrate a restructuring of specific lipid species, particularly
phosphatidylcholines (PC) and triacylglycerols (TAG), within the circulating lipid pool of PPARδ and PPARg agonist-treated mice. The TAG species
increased in the PPARδ agonist-treated mice marked in red are decreased in the PPARg agonist-treated mice marked in blue.
Roberts et al. Genome Biology 2011, 12:R75
http://genomebiology.com/2011/12/8/R75
Page 3 of 191e, f). Interrogating the loadings plots of the multivariate
models, both agonists stimulated increases in the consti-
tuents of the ω-6 fatty acid pathway, demonstrating that
both agonists stimulate the activity of desaturases. How-
ever, the most profound difference between the two
agonists was characterized by decreased concentrations
of the long chain saturated fatty acids (C19:0, C20:0,
C21:0 and C22:0) following PPARδ agonist treatment,
while free palmitic acid, stearic acid and its desaturated
forms (C18:1 and C18:2) increased in compensation.
Given the important role adipose tissue plays in mod-
ulating the lipid composition of blood serum, liquid
chromatography (LC)-MS was used to profile intact
lipids in blood serum (Figure 1g). While both agonists
induced changes in polar lipids, the most dramatic con-
trast was apparent in changes in the TAG content. The
PPARδ agonist induced increases in the concentration
of a number of circulating TAG species containing
C16:0, C18:0 and C18:1 fatty acids in blood serum,
while the same TAG species were decreased following
PPARg agonist treatment (Figure 1g). Thus, stimulation
of PPARδ increased the mobilization of TAGs, and
PPARg stimulation increased the sequestration of TAGs.
These metabolic changes demonstrate that while both
agonists induced the activity of desaturases, the PPARδ
agonist was characterized by a reduction in fatty acid
chain length consistent with increased b-oxidation.
However, because both agonists influence metabolism in
a range of organs, this study was complemented with an
analysis of 3T3-L1 adipocytes to examine adipocyte
metabolism in isolation.
Metabolomic analysis of 3T3-L1 adipocytes treated with
the PPAR agonists
To profile total fatty acid changes, GC-MS of fatty acid
methyl esters was again applied in conjunction with
multivariate statistics (Figure 2a). The loadings plots of
the partial least squares-discriminant analysis (PLS-DA)
models of the data were again used to determine the
key metabolic changes in total fatty acid profiles induced
by the two agonists (Figure 2b, c). Similar to the
changes detected in adipose tissue, both agonists
affected the ω-6 fatty acid pathway, with the PPARδ
agonist increasing the concentrations of a number of
the later pathway intermediates, while the PPARg ago-
nist decreased g-linolenate, and increased dihomo-g-
linolenate. PPARδ activation also stimulated an increase
in the end products of the ω-3 fatty acid pathway
(C20:5, C22:5 and C22:6).
However, the major difference between the two ago-
nists was a general decrease in the concentration of
fatty acids observed in PPARδ agonist-treated cells)
while PPARg stimulation induced a relative change in
overall chain length characterized by decreases in the
concentrations of the medium chain fatty acids (C13:0,
C14:0, C15:0, C16:1, C17:0, C17:1, C18:1) and a conco-
mitant increase in the steady state concentrations of the
long chain fatty acids (C20:0 and C22:0). These changes
in total fatty acids were also represented in the free fatty
acid profile measured by DI-MS and modeled by multi-
variate analysis (Figure 2d, e).
Changes in the composition of complex lipids was
observed in the PPARδ activated 3T3-L1 adipocytes. An
increase in the concentration of a number of glycero-
phosphocholine and phosphatidylcholine (PCs) species
was ascertained and this was accompanied by a decrease
in the concentration of specific TAGs (Table 1). Unlike
the shift from TAGs to phospholipids induced by
PPARδ, the activation of PPARg produced a more com-
plex remodeling of TAGs with an increase in longer
chain and desaturated fatty acids, which dominated the
resultant PLS-DA model (Table 1). In addition, a range
of PCs, glycerophosphocholines, glycerophosphoethano-
lamines and glycerophosphoinsoitols decreased in con-
centration while the concentration of several cholesterol
esters increased (data not shown).
A combination of both NMR spectroscopy and GC-
MS analysis of aqueous metabolites readily distinguished
the action of the two PPAR receptors. PPARδ activation
increased the concentration of the peroxisomal oxida-
tion product adipic acid, while PPARg stimulation
decreased the concentration of carnitine, the main
transporter of fatty acids across the mitochondrion. The
PPARδ agonist also decreased the concentration of glu-
cose and other carbohydrates in adipose cells, as well as
increased the concentration of citrate and glutamate
(the latter in fast exchange with 2-oxogluturate). While
PPARg stimulation also decreased the concentration of
glucose, it also decreased the concentrations of the later
tricarboxylic acid (TCA) cycle metabolites. Changes in
the steady state concentrations of specific metabolites
and corresponding metabolic pathways in 3T3-L1 adipo-
cytes treated with either the PPARδ or PPARg agonist
are summarized in Figure 2f, g.
To assess how metabolism in the 3T3-L1 cells influ-
enced their environments, metabolite changes in the
media were investigated using a combination of GC-MS,
probing fatty acid export from the cells, and
1HN M R
spectroscopy, determining changes in aqueous phase
metabolites. While the PPARδ agonist did not affect
fatty acid export compared with cells treated with the
vehicle control, PPARg reduced the export of fatty acids,
particularly of saturated fatty acids (palmitate, P =0 . 0 1 ,
23% reduction; stearate, P = 0.04, 19% reduction). How-
ever, PPARδ activation markedly reduced the concentra-
tions of amino acids in the PPARδ cell culture media
compared with both the control group and cells treated
with the agonist, in particular the BCAAs leucine (P <
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Figure 2 Metabolomic investigation of PPARδ and PPARg activation in 3T3-L1 adipocytes. (a) Chromatogram of GC-MS analysis of the
total fatty acid content of 3T3-L1 adipocytes treated with the PPARδ agonist. Key metabolites are labeled. (b) Plot of partial least squares-
discriminant analysis (PLS-DA) scores showing the clustering of GC-MS chromatograms from the lipid fraction of 3T3-L1 adipocytes treated with
100 nM and 1 μM PPARδ agonist GW610742 compared with the control group: 1 μM PPARδ agonist dose (diamonds; n = 6), 100 nM PPARδ
agonist dose (filled circles; n = 6), control (filled squares; n =6 )( R
2(X) = 77%, Q
2 = 75%). (c) Plot of PLS-DA scores showing the clustering of GC-
MS chromatograms from the organic fraction of 3T3-L1 adipocytes treated with 10 nM PPARg agonist GW347845 and 100 nM PPARg agonist
GW347845 compared with the control group: 10 nM PPARg agonist dose (asterisks; n = 6), 100 nM PPARg agonist dose (squares; n = 6), control
(filled squares; n =6 )( R
2(X) = 87%, Q
2 = 90%). (d) Plot of PLS-DA scores showing the clustering of DI-MS negative mode ionization
chromatograms from the organic fraction of 3T3-L1 adipocytes treated with 100 nM and 1 μM PPARδ agonist GW610742 compared with the
control group: 1 μM PPARδ agonist dose (diamonds; n = 6), 100 nM PPARδ agonist dose (filled circles; n = 6), control (filled squares; n =6 )( R
2(X)
= 70%, Q
2 = 85%). (e) Plot of PLS-DA scores showing the clustering of DI-MS negative mode ionization chromatograms from the organic
fraction of 3T3-L1 adipocytes treated with 10 nM PPARg agonist GW347845 and 100 nM PPARg agonist GW347845 compared with the control
group: 10 nM PPARg agonist dose (asterisks; n = 6), 100 nM PPARg agonist dose (squares; n = 6), control (filled squares; n =6 )( R
2(X) = 86%, Q
2 =
88%). (f) Key steady state metabolic changes detected in 3T3-L1 adipocytes following treatment with the PPARδ agonist GW610742 using a
combination of
1H NMR spectroscopy and GC-MS. Metabolites increased in concentration are labeled in red, and metabolites decreased in
concentration are labeled in blue. (g) Key steady state metabolic changes detected in 3T3-L1 adipocytes following treatment with the PPARg
agonist GW347845 using a combination of
1H NMR spectroscopy and GC-MS. Metabolites increased in concentration are labeled in red, and
metabolites decreased in concentration are labeled in blue. (h) Changes in BCAAs in the culture media of PPARδ agonist-treated 3T3-L1 cells **P
< 0.005, ****P < 0.0001. Error bars represent standard errors of the mean.
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Page 5 of 190.0001), isoleucine (P = 0.002) and valine (P = 0.005)
(Figure 2h). Concomitantly, the steady state intracellular
concentration of valine was increased in PPARδ agonist-
treated cells (P < 0.05)
13C-labelled substrate studies
In order to identify the metabolic mechanisms asso-
ciated with PPARδ and PPARg activation in white adi-
pose tissue and 3T3-L1 adipocytes, the
13C-labeled
substrates 1-
13Cglucose and U-
13C-palmitate were used
to monitor flux through glycolytic and fatty acid oxida-
tive pathways.
The use of 1-
13C glucose and GC-MS readily distin-
guished the two agonists. Examination of the aqueous
phase by GC-MS revealed that lactate, glutamate (read-
ily labeled from the TCA cycle from labeled 2-oxogluta-
r a t e )a n ds u c c i n a t ef r o mP P A R δ agonist-treated cells
were enriched with
13C when compared to control (Fig-
ure 3a). In contrast, the PPARg agonist caused a reduc-
tion in labeling of lactate, succinate and glutamate
compared to the vehicle-treated cells (Additional file 1).
The PPARδ agonist also decreased labeling of the med-
ium chain fatty acid palmitate from 1-
13C glucose, while
Table 1 Lipid species altered in concentration in 3T3-L1
adipocytes treated with either the PPARδ agonist
GW610742 or the PPARg agonist GW347845
PPARδ PPARg
Increased Decreased Increased Decreased
PC 32:0 (16:0/
16:0)
TAG 52:1 TAG 48:0 TAG 44:2
PC 34:0 TAG 52:5 TAG 50:1 TAG 44:1 (15:0/15:0/
14:1)
PC 34:1 TAG 52:6 TAG 52:4 TAG 44:1 (15:1/14:0/
15:0)
PC 35:5 TAG 53:2 TAG 54:6 TAG 45:2
PC 36:1 TAG (18:3/17:0/
19:0)
TAG 54:5 TAG 46:2
PC 36:2 TAG (18:1/17:1/
19:1)
TAG 54:4 TAG 47:2
PC 36:3 TAG (20:1/17:1/
17:1)
TAG 47:3
TAG (20:1/15:0/
19:2)
TAG 48:3
TAG (20:1/15:1/
19:1)
TAG 48:2
TAG 49:3
TAG 50:3
Species were detected using LC-MS. Lipids identified in the VIP/coefficient
plots as significantly contributing to separation in the principal components
analysis (PCA) and PLS-DA models built for the LC-MS analysis of the organic
metabolite fraction (P < 0.05 for significant contribution to the first
component of the PLS-DA plot). The control group (n = 6) was compared with
the PPARδ agonist-treated group (n = 6) or PPARg agonist-treated group (n =
6). All triacylglycerols (TAGs) were observed as ammonium adducts. Where
stated, exact composition was confirmed by tandem mass spectrometry (MS/
MS) and phosphocholines (PCs) were identified by monitoring for the loss of
the choline head group during MS/MS.
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Figure 3 Stable isotope flux analysis of PPARδ agonist-treated
3T3-L1 adipocytes. (a) Graphs showing the M+1/M isotope ratio
13C enrichment of lactate, glutamate and succinate analyzed by GC-
MS of the aqueous fraction and M+1/M isotope ratio
13C
enrichment of palmitic acid analyzed by GC-MS of the organic
fraction from control (n = 6) and PPARδ agonist-treated (n = 6) 3T3-
L1 cells incubated with 1-
13C glucose. *P < 0.05, **P < 0.01. The
metabolites have been mapped to the glycolysis and TCA cycle
metabolic pathways. Red indicates a metabolite increased in
13C
enrichment by PPARδ activation. (b) Graphs showing the M+1/M
isotope ratio
13C enrichment of malate, glutamate, fumarate and
succinate analyzed by GC-MS of the aqueous fraction and
enrichment of arachidic acid, stearic acid, palmitoleic acid, myristic
acid and lauric acid analyzed by GC-MS of the organic fraction from
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chain fatty acid arachidate. In addition,
13C NMR spec-
troscopy of the organic fraction of control and PPARδ
agonist-treated adipocytes incubated in media contain-
ing 1-
13C glucose showed that glycerol and esterified
glycerol from PPARδ agonist-treated cells had reduced
enrichment compared with the control group (Addi-
tional file 2).
Similarly, the labeled substrate U-
13C palmitate readily
distinguished the two agonists. Assessment of the aqu-
eous phase by GC-MS indicated that several TCA cycle
intermediates from PPARδ agonist-treated adipocytes
were enriched compared to control cells (Figure 3b).
Investigation of the organic phase by GC-MS demon-
strated that the fatty acids downstream of palmitic acid
in the b-oxidation pathway showed greater
13Ce n r i c h -
ment in PPARδ agonist-treated cells; as did the Δ-9
desaturation product of palmitic acid. Simultaneously,
the enrichment of fatty acids upstream of palmitic acid
in the fatty acid synthesis pathway was reduced in
PPARδ agonist-treated cells (Figure 3b).
GC-MS analysis of the aqueous phase of cells incu-
bated in U-
13C palmitate indicated that the early TCA
cycle intermediates exhibited decreased
13Ce n r i c h m e n t
in PPARg agonist-treated adipocytes when compared to
control adipocytes (Additional file 1). Assessment of the
organic phase by GC-MS indicated that the
13Ce n r i c h -
ment of the long chain fatty acid arachidate was
increased in the PPARg agonist-treated cells when com-
pared to control (Additional file 1). Concurrently, the
13C enrichment of the shorter chain fatty acid myristate
was decreased.
Respirometric analysis
To further characterize the PPARδ induced upregulation
of oxidative pathways in adipocytes, the oxygen con-
sumption of PPARδ agonist-treated and control 3T3-L1
cells was measured both when using fatty acid as sub-
strate and during isolated electron transport chain com-
plex IV oxidation using in situ studies in a Clarke type
oxygen electrode. Both complex IV and fatty acid oxida-
tion were significantly increased in the adipocytes
exposed to the PPARδ a g o n i s tw h e nc o m p a r e dt oc o n -
trol adipocytes (Figure 4a, b). This was accompanied by
a profound decrease in TAGs as measured by Oil Red
O staining of neutral lipids (Figure 4c).
Microarray transcriptomic analysis
The combination of steady state metabolomic changes
in adipose tissue and adipocytes and isotope labeling
studies indicated a profound upregulation of glucose
and fatty acid oxidation following PPARδ activation. To
investigate these changes in more detail, we moved
focus to the transcriptome using microarray analysis of
PPARδ activation in adipocytes. Of the 45,281 probes
utilized, 13,718 were expressed above the background
defined by the negative control probe. From these, 2,349
were determined to be differentially expressed with a
95% confidence level between PPARδ agonist-treated
and control 3T3-L1 adipocytes. In addition to the uni-
variate analysis, multivariate models were also built
using the total normalized data (Figure 5a). The 6% of
transcripts most responsible for separation in the multi-
variate models were then examined (3% with the highest
positive contribution to principal component 1 and 3%
with the highest negative contribution to principal com-
ponent 1 in PPARδ agonist-treated cells as identified in
the multivariate models). The multivariate analysis indi-
cated that the mRNA of genes involved in a number of
key metabolic pathways was altered following PPARδ
activation. The Reactome Skypainter tool was then uti-
lized to determine which pathways and reactions were
statistically overrepresented by the 3% most increased
and 3% most decreased transcripts in PPARδ agonist-
treated cells identified in the multivariate models (Table
2; Figure 5b) [13].
The expression of genes encoding proteins involved in
the mitochondrial b-oxidation pathway and the peroxi-
somal fatty acid b-oxidation pathway was increased in
PPARδ agonist-treated cells. Alongside these changes
were an increase in the transcription of genes involved
in both mitochondrial and peroxisomal biogenesis and
maintenance. The transcription of several genes whose
products play a role in the glycolytic metabolic pathway
and the TCA cycle was also upregulated in PPARδ ago-
nist-treated cells. In addition, there was a detected
increase in the concentrations of expressed mRNA for
components of the electron transport chain, and genes
involved in fatty acid desaturation (Table 2; Additional
file 3).
The results from the steady state metabolomic experi-
ments in adipose tissue and adipocytes and the isotope
labeling studies suggest PPARg activation has a pro-
nounced effect on glucose utilization and fatty acid
synthesis and metabolism in adipocytes. Transcriptional
changes were investigated by DNA microarrays to
further define the changes associated with PPARg activa-
tion in adipocytes. Of the 45,281 probes utilized, 13,755
were expressed above the background defined by the
negative control probe. From these, 3,282 were deter-
mined to be differentially expressed with a 95%
control (n = 6) and PPARδ agonist-treated (n = 6) 3T3-L1 cells
incubated with U-
13C palmitate. *P < 0.05, **P < 0.01,***P < 0.005.
Red indicates a metabolite increased, and blue indicates a
metabolite decreased in
13C enrichment by PPARδ activation. Parent
ions were used to calculate ion ratio. Error bars represent standard
errors of the mean.
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Figure 4 Respirometric analysis of PPARδ agonist-treated 3T3-L1 adipocytes. (a) Graph showing the respiratory rates of in situ
permeabilized control (n = 3) and PPARδ agonist-treated (n = 3) 3T3-L1 cells performing b-oxidation using palmitoyl-carnitine measured using a
Clark-type oxygen electrode. *P = 0.05. (b) Graph showing the respiratory rates of the electron transport chain complex IV of in situ
permeabilized control (n = 3) and PPARδ agonist-treated (n = 3) 3T3-L1 cells measured using a Clark-type oxygen electrode. *P < 0.05. (c)
Spectrophotometric measurement at 510 nm of Oil Red O eluted from stained 3T3-L1 cells treated with DMSO control (n = 3) or 100 nM (n =3 )
or 1 μM( n = 3) of the PPARδ agonist GW610742. Error bars represent standard errors of the mean.
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Figure 5 Transcriptomic analysis of PPARδ and PPARg activation in 3T3-L1 adipocytes. (a) Plot of PLS-DA scores showing the clustering of
gene transcription in control and PPARδ agonist-treated 3T3-L1 adipocytes as measured with microarray analysis: PPARδ agonist-treated (filled
circles; n = 6), control (filled squares; n =6 )( R
2(X) = 35%, Q
2 = 90%). (b) Diagram showing the effect of PPARδ activation on the integration of
the energy metabolism pathways of 3T3-L1 adipocytes based on the combination of results from the metabolomic, transcriptomic and stable
isotope labeling studies. Red indicates an increase in concentration or expression in cells treated with the PPARδ selective agonist GW610742.
Blue indicates a decrease in concentration in cells treated with the PPARδ selective agonist GW610742. (c) Plot of PLS-DA scores showing the
clustering of gene transcription in control and PPARg agonist-treated 3T3-L1 adipocytes as measured with microarray analysis: PPARg agonist-
treated (filled circles; n = 6), control (filled squaresl n =6 )( R
2(X) = 42%, Q
2 = 84%).
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Page 9 of 19confidence limit. Multivariate models were then built
using the total normalized data (Figure 5c). The 6% of
transcripts most responsible for separation in the multi-
variate models (that is, those contributing most to the
total variance of the multivariate model) were then
examined using a combination of multivariate analysis
and the Reactome Skypainter tool as described above
[13]. The pathways and reactions that were statistically
overrepresented by the 3% most increased and 3% most
decreased transcripts in PPARg agonist-treated cells
identified in the multivariate models are shown in Table
3, Figure 5c, and Additional file 4.
The expression of genes encoding proteins involved in
the glycolytic metabolic pathway were upregulated in
PPARg agonist-treated cells. In addition, the expression
o ft h eg e n ee n c o d i n gt h eT C Ac y c l ee n z y m ei s o c i t r a t e
dehydrogenase was identified as decreased, suggesting
that citrate was being channeled to fatty acid synthesis
rather than being metabolized by the TCA cycle. PPARg
activation was also discerned to significantly affect the
transcription of genes responsible for the remodeling
and metabolism of lipids. Genes for fatty acid desa-
turases (Scd2 and Fads3) were increased in expression
following PPARg activation. The transcripts of a number
of genes that favor conditions of fatty acid synthesis
were also increased in concentration in the adipocytes
following treatment with the PPARg agonist. Concomi-
tantly, the expression of genes encoding enzymes that
catalyze the hydrolysis of medium and long chain acyl-
CoAs to free fatty acids and coenzyme A (CoA) was
upregulated in the treated adipocytes (Acot7 and
Nudt19). In addition, the transcription of an insulin
responsive fatty acid transporter gene (Slc27a1) respon-
sible for the import of long chain fatty acids into adi-
pose tissue undergoing high levels of TAG synthesis was
increased.
Several genes involved in the restructuring and remo-
deling of complex lipids were also affected by PPARg
activation. There was an increase in transcription of
genes encoding enzymes responsible for conversion of
lysophospholipids to phospholipids, favoring polyunsatu-
rated fatty acyl-CoAs as acyl donors (lysophosphatidyl-
choline acyltransferase 3 acyltransferase). In addition,
mRNA transcripts of genes encoding products that reg-
ulate lipolysis, alongside other metabolic processes,
including gluconeogenesis, were increased in the PPARg
agonist-treated cells (platelet activating factor acetylhy-
drolase 2 lipase, angiopoietin-related protein 4 and
nuclear receptor corepressor 1). Additionally, transcrip-
tion of the PPAR transcriptional coactivator gene chro-
modomain helicase DNA binding protein 9 was
upregulated in the PPARg agonist-treated adipocytes.
Several transcripts were increased in both PPARδ and
PPARg agonist-treated cells, principally involved with
glycolysis and lipid metabolism. However, PPARδ activa-
tion was unique in its effect on the citric acid cycle, the
electron transport chain and fatty acid b-oxidation
(Tables 2 and 3).
Discussion
A comprehensive array of analytical techniques was used
in a metabolomic investigation to study the metabolic
Table 2 The pathways statistically significant in the 3% most increased transcripts in PPARδ agonist-treated cells
identified in the multivariate models
P-
value
Pathway Transcripts increased in PPARδ agonist-treated cells mapping to the pathway
6.3e-
08
Glucose regulation of insulin secretion Cycs, Etfa, Mdh2, Aldoa, Dld, Ndufb10, Ndufb9, Atp5a1, Ndufb5, Gpi1, Tpi1, Pgk1, mt-Co2,
Sdhb, Sdhd, mt-Atp6, Cox7b, Ndufb2
1.3e-
06
Integration of energy metabolism Cycs, Etfa, Mdh2, Aldoa, Dld, Ndufb10, Ndufb9, Atp5a1, Cpt2, Ndufb5, Gpi1, Tpi1, Pgk1, mt-Co2,
Sdhb, Sdhd, mt-Atp6, Cox7b, Ndufb2
1.3e-
06
Diabetes pathways Hspa8, Cycs, Wdr89, Etfa, Mdh2, Aldoa, Dld, Ndufb10, Myo5a, Ndufb9, Atp5a1, Rps21, Rps3a,
Sec11c, Ndufb5, Gpi1, Tpi1, Pgk1, Sdhb, mt-Co2, Dnajb9, Sdhd, mt-Atp6, Cox7b, 2900062L11Rik,
Ndufb2
8.5e-
06
Electron transport chain Cycs, Ndufb5, Etfa, mt-Co2, Ndufb10, Sdhb, Sdhd, Ndufb9, Cox7b, Ndufb2
7.1e-
04
Citric acid cycle (TCA cycle) Dld, Sdhb, Sdhd, Mdh2
1.4e-
03
Mitochondrial fatty acid b-oxidation of saturated
and unsaturated fatty acids
Hadhb, Acadl, Acadvl
1.6e-
03
Glycolysis Aldoa, Tpi1, Pgk1, Gpi1
4.5e-
03
Metabolism of lipids and lipoproteins Agpat3, Hadhb, Ppp1cc, Slc27a1, Lass2, Angptl4, Cpt2, Akr1b3, Abcd3, Acadl, Sgpl1, Acaa2,
Acadvl, Mod1, Hmgcs2, Adfp
7.8e-
03
Formation of acetoacetic acid in synthesis of
ketone bodies
Hmgcs2, Acaa2
Transcripts in bold were increased in both PPARδ and PPARg agonist-treated cells.
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mice and 3T3-L1 adipocytes following either PPARδ or
PPARg activation, to understand the role of these
nuclear hormone receptors in treating T2DM and obe-
sity. Our metabolomic analysis demonstrates the large
differences between the action of the two receptors,
with PPARδ associated with a profound increase in oxi-
dation of glucose, fats and amino acids, and PPARg
associated with the sequestration and restructuring of
lipids within adipose tissue. This was confirmed by not
only observing changes in steady state metabolite con-
centrations but also using stable isotope techniques to
probe flux, oxygen consumption measurements and
monitoring transcriptional changes, with agreement
across these different tiers of biological organization.
PPARδ activation is known to increase the oxidation
of fatty acids [11,14] and this was confirmed by both the
relative increase in short chain fatty acids compared
with long chain fatty acids in both adipose tissue and
3T3-L1 cells as well as respiration rate measurements
and the increased concentration of adipic acid, the pri-
mary end product of peroxisomal b-oxidation [15], in
cells. Transcriptomic analysis also indicated an increase
in b-oxidation, with increases in the transcription of a
panel of genes involved in fatty acid mitochondrial and
peroxisomal b-oxidation (Table 2; Cpt2, Acadvl, Acadl,
Hadhb, Acaa2, Abcd3, Ech1, Peci). The oxidation of fats
was directly followed by monitoring the metabolism of
U-
13C palmitate, with increased labeling of shorter chain
fatty acids following the stimulation of PPARδ. PPARδ
stimulation also increased the TCA cycle rate, as indi-
cated by following the labeling patterns induced by 1-
13C glucose, the increased labeling of TCA cycle inter-
mediates during metabolism of U-
13C palmitate, and the
increased steady state concentrations of TCA cycle
intermediates in 3T3-L1 cells. Transcriptomic analysis
substantiated this finding, with the expression of genes
with roles in glycolysis and the TCA cycle significantly
increased upon PPARδ activation (Table 2; Tpi1, Gpi1,
Aldoa, Pgk1, Mdh2, Sdhb, Sdhd, Dld).
Wang and colleagues [11] discussed the upregulation
of fatty acid oxidation in brown adipose tissue following
the over expression of PPARδ in terms of the expression
of a range of enzymes involved in uncoupling (uncou-
pling protein 1 and 3), fatty acid oxidation (acyl-CoA
oxidase, muscle carnitine palmitoyltransferase-1, long
Table 3 The pathways statistically significant in the 3% most increased transcripts in PPARg agonist-treated cells
identified in the multivariate models
P-
value
Pathway Transcripts increased in PPARg agonist-treated cells mapping to the
pathway
6.4e-
05
Glycolysis Aldoa, Pgam1, Pfkl, Gapdh, Gpi1
1.1e-
03
Gluconeogenesis Aldoa, Slc25a11, Pgam1, Gapdh, Gpi1
1.2e-
03
Ca
2+ signaling via IP3 binding to the IP3 receptor, opening the
endoplasmic reticulum Ca
2+ channel
Itpr2, Itpr1
1.8e-
03
Phospholipase C-mediated signaling events Prkaca, Itpr2, Itpr1, Adcy6, Pde1b
2.5e-
03
Hormone-sensitive lipase-mediated triacylglycerol hydrolysis Prkaca, Abhd5, Ppp1ca
2.6e-
03
Metabolism of lipids and lipoproteins Prkaca, Abhd5, Abcd3, Ppp1ca, Ncor1, Chd9, Slc27a1, Hsd17b4, Acaa2,
Sin3b, Scd2, Hmgcl, Fads3, Csnk1g2, Angptl4
3.2e-
03
Regulation of insulin secretion Prkaca, Dlst, Ndufb6, Itpr1, Gpi1, Aldoa, Ndufs6, Pgam1, Itpr2, Pfkl, Gapdh
5.8e-
03
Formation of acetoacetic acid in the synthesis of ketone bodies Hmgcl, Acaa2
8.2e-
03
Additional metabolism of carbohydrates Aldoa, Slc25a11, Pgam1, Pfkl, Gapdh, Gpi1, G6pdx
1.1e-
02
Protein kinase A-mediated events Prkaca, Pde1b
1.1e-
02
Regulation of lipid metabolism by peroxisome proliferator-
activated receptor alpha
Sin3b, Scd2, Fads3, Ncor1, Chd9, Slc27a1, Angptl4
1.7e-
02
Integration of energy metabolism Prkaca, Dlst, Ndufb6, Gpi1, Aldoa, Ndufs6, Pgam1, Pfkl, Adcy6, Gapdh
2.0e-
02
b-Oxidation of very long chain fatty acids Abcd3, Hsd17b4
0.1e-
02
Peroxisomal lipid metabolism Abcd3, Slc27a1, Hsd17b4
Transcripts in bold were increased in both PPARδ and PPARg agonist-treated cells.
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genase) as well as morphological changes within the tis-
sue. However, at the transcriptional level there was only
an increase in hormone-sensitive lipase in white adipose
tissue, despite there being reductions in adipose mass
and increased oxygen consumption in the equivalent
cell line. While the authors still infer increased oxidation
of fatty acids in white adipose tissue, our metabolomic
analysis demonstrates this in vivo in terms of the
changes of metabolites involved in fatty acid oxidation,
demonstrating the pharmacological differences between
different PPAR agonists, as well as the fact that steady
state changes in metabolite concentrations can be as
sensitive as transcriptional changes induced by a
perturbation.
One possible driving force for this increased oxidation
of both glucose and fats, and increased flux through b-
oxidation and the TCA cycle, is the increased expression
of the components of the electron transport chain
(Table 2; Ndufb5, Ndufb10, Ndufb9, Ndufb2, Cys, Etfa,
mt-Co2, Sdhb, Sdhd, Cox7b, mt-Atp6). This finding in
adipocytes is concordant with previous studies per-
formed in skeletal muscle that demonstrated that
PPARδ activation increases the expression of several
electron transport chain proteins, including cytochrome
c and cytochrome oxidase [16]. Furthermore, respirome-
try studies confirmed that independently of fatty acid
oxidation the oxidative rate of electron transport chain
complex IV was increased upon PPARδ activation. This
effect was independently observed by the increase in the
creatine concentration within 3T3-L1 adipocytes treated
with the PPARδ agonist, demonstrating an alteration to
the high energy phosphate buffering capacity of the
cells. These findings are consistent with previously
reported observations in skeletal muscle. A decrease in
the intramyocellular lipid-to-total creatine ratio in the
soleus and tibialis anterior muscles from Sprague-Daw-
ley rats treated with the selective PPARδ agonist
GW610742 has been detected using in vivo
1HN M R
spectroscopy [17]. In addition, an increase in the con-
centrations of creatine and phosphocreatine were
detected in the gastrocnemius of ob/ob mice following
pharmacological activation of PPARδ [14].
Intriguingly, this increased oxidative capacity also
manifested itself in increased amino acid metabolism, as
indicated by the decrease in BCAAs in the cell culture
media from PPARδ agonist-treated 3T3-L1 cells. PPARδ
agonists have been linked to muscle atrophy [18], and
one potential cause is the increased oxidation of amino
acids, producing cachexia through increased protein
turnover. Metabolomic profiling of obese versus lean
humans has also recently indicated that BCAA concen-
trations are increased in obesity in the context of high
fat consumption [19], which may be correlated with
decreased PPARδ activity. BCAAs have also been cau-
sally implicated in the pathogenesis of insulin resistance
[19,20], indicating that one possible mechanism by
which PPARδ improves insulin resistance is by reducing
the concentration of BCAAs.
In contrast to the PPARδ-mediated upregulation of
oxidative pathways, PPARg activation has previously
been linked to an increase in glucose uptake and glyco-
lysis in white adipose tissue [2,21]. A consistent observa-
tion from both the white adipose tissue and 3T3-L1
adipocytes exposed to the PPARg agonist was a decrease
in the concentration of glucose and other carbohydrate
species. Transcriptomic analysis of the 3T3-L1 cells
showed that the enzymes of glycolysis were increased in
expression, but the labeling of lactate from 1-
13Cg l u -
cose was decreased compared with the control group.
This was also associated with an increase in the concen-
trations of citrate and succinate and decreases in fuma-
rate and malate. The 1-
13C glucose labeling experiment
and increased citrate concentration demonstrate that
the increased glycolytic flux, and hence ability to meta-
bolize extracellular glucose, is in fact associated with
fatty acid synthesis. In addition, the microarray analysis
of mRNA expression in 3T3-L1 adipocytes demon-
strated a decrease in expression of isocitrate dehydro-
genase, which in turn will stimulate the export of citrate
out of mitochondria into the cytosol for fatty acid synth-
esis. Transcriptomic analysis also highlighted the signifi-
cant upregulation in the expression of genes involved in
calcium and calmodulin signaling within adipocytes
treated with the PPARg agonist GW347845. Calcium
signaling increases GLUT4 translocation to the plasma
membrane, increasing glucose transportation into adipo-
cytes [2].
PPARg activation also decreased flux through b-oxida-
tion, as demonstrated by both decreased intracellular
concentrations of carnitine and reduced labeling of TCA
cycle intermediates and shorter chain fatty acids from
U-
13C palmitate. In addition, the expression of acyl-CoA
thioesterase 7 and nudix-type motif 19 coenzyme A
diphosphatase enzymes, which catalyze the hydrolysis of
medium- and long-chain acyl-CoAs to FFA and CoA,
and therefore prevent the b-oxidation of medium- and
long-chain fatty acids once they are formed, was upregu-
lated in the treated adipocytes. Transcription of nuclear
receptor corepressor (Ncor1), a transcriptional repressor
indicated in the downregulation of gluconeogenesis, oxi-
dative and ketotic metabolism and lipolysis [22], was
also increased in the adipocytes treated with the PPARg
agonist.
In contrast to the differences between fatty acid oxida-
tion and synthesis associated with PPARδ and PPARg
stimulation, respectively, the changes induced in the
desaturation of fats by the different agonists showed a
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mulation increased flux through stearoyl-CoA desatur-
ase, a Δ-9 desaturase of saturated fatty acids under
PPAR expressional control [23]. For PPARδ,t h em e t a -
bolism of U-
13C palmitate in 3T3-L1 adipocytes demon-
strated increased synthesis of palmitoleate from
palmitate, while the normalized microarray data for
stearoyl-CoA desaturase and fatty acid desaturase 3
show increased expression. PPARg stimulation similarly
upregulated the expression of stearoyl-CoA desaturase.
The ω-3 and ω-6 essential fatty acid pathways were also
upregulated by both PPARδ and PPARg stimulation, as
exemplified by total fatty acid content and transcrip-
tional changes. The Δ 6-desaturase is integral to both
pathways; the enzyme introduces the initial double bond
into linoleate forming g-linolenate in the ω-6 pathway
and introduces the double bond into linolenate forming
stearidonic acid. The Δ 6-desaturase gene is known to
contain a peroxisome proliferator response element and
is under PPAR transcriptional control [24] and may be
the point of transcriptional control for both receptors
within the essential fatty acid pathways.
The fundamental differences in fatty acid metabolism
between the two agonists had a profound effect on the
remodeling of triglycerides within adipose tissue. A
decrease in the concentration of several TAGs was
observed in the 3T3-L1 adipocytes following PPARδ
activation. Within white adipose tissue several free fatty
acids, such as palmitic acid, were increased in concen-
tration despite their total concentration across lipid spe-
cies within the tissue decreasing. These metabolic
alterations are complicit with previously observed
changes indicating that PPARδ activation in white adi-
pose results in an increase in lipolysis in the tissue [25].
The results are corroborated by our observation, made
using heteronuclear single quantum coherence (HSQC)
NMR spectroscopy, that there was a decrease in the
enrichment of glycerol in adipocytes incubated with 1-
13C glucose and treated with PPARδ agonist when com-
pared to control cells, indicating reduced synthesis of
glycerol from glucose on activation of PPARδ.T h i s ,i n
part, could also explain the decrease in the concentra-
tion of TAGs due to reduced synthesis. Thus, PPARδ
activation leads to a mobilization of lipid stores and
concomitant decrease in the synthesis of the complex
lipids such as TAGs required for fatty acid storage.
A distinct restructuring of the TAG pool also
occurred as a consequence of PPARg activation; the
length and desaturation of fatty acids esterified to TAGs
in cultured adipocytes was increased due to increased
activities of fatty acid elongase and Δ-9 desaturase in
white adipose tissue. PPARg also directly regulates the
glycerol kinase promoter and therefore promotes the
esterification of fatty acids into TAGs [2]. Microarray
analysis indicated that expression of genes encoding
enzymes that catalyze the formation of phospholipids
from lysophospholipids (lysophosphatidylcholine acyl-
transferase 3 acyltransferase), with a bias for incorpora-
tion of polyunsaturated fatty acid moieties, was
increased in adipocytes treated with PPARg [26]. In
addition, the expression of mRNA encoding platelet
activating factor acetylhydrolase 2 lipase, a lipase selec-
tive for phospholipids with short acyl chains at the sn-2
position, and angiopoietin-related protein 4, an inhibitor
of lipoprotein lipase and therefore lipolysis, was
increased in the PPARg agonist-treated 3T3-L1 cells
[27]. Angiopoietin-related protein 4 is a known target
gene for PPARδ in muscle, and its apparent upregula-
tion in adipose tissue by PPARg identified in this study
may give further insight into the tissue-specific targets
of the PPAR isoforms [28]. Furthermore, the upregula-
tion of the transcription of genes involved in calcium
signaling as a consequence of PPARg activation may
p l a yar o l ei nd e f i n i n gt h ec o n s t i t u e n t so ft h ec o m p l e x
lipid pool within the adipocytes. An increase in intracel-
lular calcium stimulates the activity of fatty acid
synthase, stimulates lipogenesis, inhibits basal lipolysis,
and promotes TAG accumulation within murine and
human adipocytes [2].
The concentrations of several metabolites in the
polyol pathway were decreased following PPARδ activa-
tion, presumably attributable to increased glucose cata-
bolism. On the other hand, PPARg activation increased
the production of glucitol and fructose, with sorbitol
dehydrogenase being increased in expression in adipo-
cytes following treatment. Given the role that the polyol
pathway and aldose reductase have in the formation of
toxic advanced glycation end-products and the resultant
diabetic complications, such as neuropathy, nephropathy
and retinopathy, a decrease in the activity of this path-
w a ym a yp r o v eas i g n i f i c a n ta nti-diabetic effect of
PPARδ activation [29].
One of the most striking differences between the two
agonists in vivo was the mobilization of TAGs derived
from C16:0, C18:0 and C18:1 fatty acids, representing in
part the most highly synthesized fatty acids from glu-
cose, in blood plasma by PPARδ activation and a reduc-
tion in the same TAGs by PPARg activation. This would
appear to be contrary to previous studies reporting
PPARδ activation to be associated with a reduction of
TAGs in blood plasma as a result of increased oxidation
in skeletal muscle and white and brown adipose tissue
[10,11,30]. However, it should be noted that different
studies have used different agonists with differing rela-
tive doses and regimes, and so the effectiveness of short
term lipid lowering in blood plasma may be variable.
The detected increase in certain TAGs containing C16
and C18 saturated and monounsaturated fats in blood
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following PPARδ activation most likely indicate an
increase in mobilization of TAG stores as a result of
increased oxidation of fats in skeletal muscle. However,
as the mobilization of fat stores continues across time,
presumably these TAGs in the blood plasma will
decrease in concentration, reflecting the anti-atherogenic
properties of PPARδ agonists.
Conclusions
It has been shown that the anti-diabetic and anti-obesity
effects of PPARδ activation are brought about, in part,
by a decrease in fatty acid synthesis and fat storage
within synthesized TAG depots and a concomitant
mobilization of complex lipid fat stores. The mobiliza-
tion of lipid energy stores is accompanied by upregula-
tion of not only fatty acid oxidation but also
carbohydrate and amino acid oxidative metabolism in
white adipose, a tissue not traditionally thought of as
being energetic and oxidative. This novel finding
demonstrates PPARδ’s ability to control global oxidation
within adipose tissue. Essential to this process is the
integration and co-ordination of the energy metabolism
pathways, which PPARδ accomplishes by upregulating
the transcription of a series of genes involved in glycoly-
sis, the TCA cycle, the electron transport chain and
fatty acyl b- o x i d a t i o n .T h i si si nm a r k e dc o n t r a s tt o
PPARg activation, where metabolic restructuring
increases fatty acid synthesis in addition to the ultimate
sequestration of fatty acids into triglycerides. Thus,
while both agonists alleviate the effects of T2DM by
potentially decreasing the lipid load on peripheral tissue
and the induction of insulin resistance by lipotoxicity
[31], stimulation of PPARδ m a ya l s or e d u c eo b e s i t y ,
thus being a potent target for the treatment of the meta-
bolic syndrome.
Materials and methods
Ob/Ob mouse study and tissue collection
All animal studies were performed within the relevant
local legislation. Two-month-old male ob/ob mice (Jack-
son Labs, Bar Harbor, ME, USA) were fed standard
laboratory chow ad libitum under controlled tempera-
ture, lighting and humidity. During the studies, body
weight and food consumption (cage average) were
recorded. The ob/ob mice were weight matched (mean
weight 46 ± 1 g), assigned to three groups of eight and
dosed orally daily with vehicle control, the PPARδ ago-
nist GW610742 (30 mg/kg) or the PPARg agonist
GW347845 (5 mg/kg). Serum was collected via cardiac
stick under isoflourane anesthesia at completion of the
s t u d yo nd a y1 5 .W h i t ea d i p o s et i s s u e( g o n a d a lf a tp a d )
was rapidly dissected (< 60 s post mortem), snap frozen
in liquid nitrogen and stored at -80°C until extraction.
3T3-L cell culture and PPAR activation
3T3-L1 preadipocytes were grown in T75 flasks and
maintained in DMEM (high glucose 4.5 g/l; Sigma-
Aldrich, Gillingham, Dorset, UK) supplemented with
10% (v/v) new born calf serum (Sigma-Aldrich), 50
units/ml penicillin, and 50 μg/ml streptomycin (Sigma-
Aldrich) in a humidified 5% CO2 incubator at 37°C. At
2 days post-confluence cells were induced to differenti-
ate with DMEM supplemented with 10% (v/v) fetal
bovine serum (FBS; Invitrogen, Paisley, Renfrewshire,
UK), 1 μM dexamethasone (Sigma-Aldrich), 0.5 mM
isobutylmethylxanthine (Sigma-Aldrich), 100 nM insulin
(Sigma-Aldrich), 50 units/ml penicillin, and 50 μg/ml
streptomycin. The cells were maintained in this media
for 72 h as this was found to improve the reproducibil-
ity of differentiation between flasks. After 72 h the med-
ium was replaced with DMEM supplemented with 10%
FBS, 100 nM insulin, 50 units/ml penicillin, and 50 μg/
ml streptomycin. The medium was subsequently chan-
ged for DMEM supplemented with 10% FBS, 50 units/
ml penicillin, and 50 μg/ml streptomycin every 48 h
[32].
At day 11 post-induction the medium on the cells was
replaced with DMEM supplemented with 10% FBS, 100
nM insulin, 50 units/ml penicillin, and 50 μg/ml strepto-
mycin containing DMSO (control; n = 6), the PPARδ
selective agonist GW610742 (n = 6 at 100 nM and 1
μM) or the PPARg selective agonist GW347845 (n =6
at 10 nM and 100 nM) for 2 days prior to cell collection
and metabolite extraction. These doses were based on
the specific affinities of the compounds for their respec-
tive receptors.
Cells were collected by removing the medium and
washing each T75 flask with 10 ml of phosphate-buf-
fered saline. Cells were then washed with 1.5 ml tryp-
sin-EDTA solution (5 BAEE units trypsin/ml, 1.8 μg
EDTA/ml; Sigma-Aldrich) for 2 minutes at 37°C to
remove the cells from the surface of the flask. DMEM
(8.5 ml) supplemented with 10% (v/v) new born calf
serum, 50 units/ml penicillin, and 50 μg/ml streptomy-
cin was added to each flask. The DMEM containing the
cells was transferred to a falcon tube and centrifuged at
200 g for 2 minutes to pellet the cells. The remaining
medium was removed and the cells washed with physio-
logical saline (0.9% NaCl) solution, and 2 ml of media
was stored for further analysis.
Tissue and 3T3-L1 metabolite extraction
Metabolites were extracted from white adipose tissue
and 3T3-L1 cells using a modified Bligh and Dyer
method [33]. Frozen white adipose tissue (approximately
100 mg for NMR and approximately 50 mg for GC-MS
analysis) was pulverized with liquid nitrogen. Methanol-
chloroform (2:1, 600 μl) was added to the white adipose
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cells) and the samples were sonicated for 15 minutes.
Chloroform-water (1:1) was then added (200 μl of each).
Samples were centrifuged (16,100 g, 20 minutes) and
the organic and aqueous phases were separated and
stored at -80°C until analysis. Of these fractions, 100 μl
of the organic phase was used for LC-MS, and the
remaining organic phase was used for GC-MS. Prior to
analysis the organic fractions were dried in a fume
hood. For the aqueous phase, 100 μl of the aqueous
phase was taken for GC-MS analysis, and the remaining
aqueous phase sample was used for
1HN M R
spectroscopy.
1H-NMR spectroscopy
Dried extracts were dissolved in 600 μlo fD 2O and buf-
fered in 0.24 M sodium phosphate (pH 7.4) containing
1 mM TSP (sodium-3-(trimethylsilyl)-2,2,3,3-tetradeu-
teriopropionate; Cambridge Isotope Laboratories, And-
over, MA, USA) and 0.02% sodium azide. Samples were
analyzed using a DRX Avance II+ spectrometer inter-
faced to a 5-mm TXI ATMA probe (Bruker BioSpin
GmbH, Rheinstetten, Germany) at a proton frequency
of 500.13 MHz. A presaturation pulse sequence for
water suppression based on a one-dimensional nuclear
Overhauser effect spectroscopy pulse sequence was used
to saturate the residual water proton signal (relaxation
delay = 2 s, t1=4 μs, mixing time = 50 ms). We col-
lected 128 and 256 transients for white adipose tissue
extracts and 3T3-L1 cell extracts, respectively, into 64 K
data points over a spectral width of 8,000 Hz at 300 K.
N M Rs p e c t r aw e r ep r o c e s s e di nA C D1 DN M RM a n -
ager (Advanced Chemistry Development Inc., Toronto,
Canada). The NMR spectra were integrated using 0.04
ppm integral regions between 0.2 and 9.56 ppm (exclud-
ing water resonance between 4.20 and 5.08 ppm). Spec-
tra were normalized to total integrated area to account
for differences in concentration between samples and
assigned by comparison with previous literature and
Chenomx NMR suite 5.0 libraries.
GC-MS analysis
Dried aqueous phase samples were derivatized using
methoxyamine hydrochloride solution (20 mg/ml in pyr-
idine; Sigma-Aldrich) and 30 μlo fN-methyl-N-tri-
methylsilyltrifluoroacetamide (Macherey-Nagel, Duran,
Germany) using the method described by Gullberg et al.
[34].
Acid-catalyzed esterification was used to derivatize the
organic phase samples. Chloroform-methanol (1:1, 0.25
ml) and BF3-methanol (10%, 0.125 ml) was added to the
organic phase and incubated at 90°C for 90 minutes.
Water (0.15 ml; ultrapurified to resistivity 18.2 MΩ cm)
and hexane (0.3 ml) were added and the samples vortex
mixed for 1 minute and left to form a bilayer. The aqu-
eous phase was discarded and the organic layer evapo-
r a t e dt od r y n e s sp r i o rt or e c o nstitution in analytical
grade hexane (200 μl) before GC-MS analysis. All GC-
MS analyses were made using a Trace GC Ultra coupled
to a Trace DSQ II mass spectrometer (Thermo Scienti-
fic, Hemel Hempstead, UK). Derivatized aqueous sam-
ples were injected splitless onto a 30 m × 0.25 mm 5%
phenylpolysilphenylene-siloxane column with a 0.25 μm
ZB-5 ms stationary phase (Phenomenex, Macclesfield,
Cheshire, UK) as described in Roberts et al. [32]. Full-
scan spectra were collected using three scans/s over a
range of 50 to 650 m/z.
The derivatized organic samples were injected with a
split ratio of 60 for white adipose tissue and 8 for 3T3-
L1 cells onto a 30 m × 0.25 mm 70% cyanopropyl poly-
silphenylene-siloxane 0.25 μmT R - F A M Es t a t i o n a r y
phase column (Thermo Scientific) as described above
and by Roberts et al. [32].
GC-MS chromatograms were processed using Xcaliber
(version 2.0; Thermo Scientific). Each individual peak
was integrated and then normalized. Overlapping peaks
were separated using traces of single ions. Peak assign-
ment was based on mass fragmentation patterns
matched to the National Institute of Standards and
Technology (USA) library and to previously reported lit-
erature. Identification of metabolites from organic phase
GC-MS analysis was supported by comparison with a
FAME standard mix (Supelco 37 Component FAME
Mix; Sigma-Aldrich).
Ultra performance LC-MS analysis
Chromatography was performed using an ACQUITY
UPLC
® system (Waters Corporation, Centennial Park,
Elstree, Hertfordshire) equipped with an Acquity UPLC
1.7 μm Bridged Ethyl Hybrid (BEH) C8 column (2.1 ×
100 mm Waters), which was kept at 65°C and coupled
to a Micromass QTof-Ultima™ with a Z-spray™ elec-
trospray source as described by Roberts et al. [32]. The
binary solvent system used was solvent A comprising
HPLC grade water (Sigma-Aldrich), 1% 1 M ammonium
acetate (NH4Ac; Sigma-Aldrich) and 0.1% formic acid
(Sigma-Aldrich) and solvent B comprising analytical
grade acetonitrile (chromosolv, Sigma-Aldrich)/isopro-
panol (Fisher Scientific, Loughborough, Leicestershire,
UK) 5:2, 1% 1 M NH4Ac, and 0.1% formic acid [35].
Mass spectrometric data were collected in full scan
mode from 100 to 1,350 m/z for adipose and 100 to
1,500 m/z for 3T3-L1 cells from 0 to 14 minutes with a
scan duration of 0.5 s and an interscan delay of 0.1 s.
For tissue extracts, the column mobile phase was held
at 85% solvent B for 0.5 minutes followed by an increase
from 85 to 100% solvent B over 0.5 to 8 minutes. The
mobile phase was then held at 100% solvent B for 4
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phase was returned to 85% solvent B held for 1.75 min-
utes to re-equilibrate the column. For serum extracts,
the column mobile phase was held at 70% solvent B for
0.5 minutes followed by an increase from 70 to 100%
solvent B over 0.5 to 6.5 minutes. The mobile phase was
then held at 100% solvent B for 3.5 minutes. Between
10 and 10.25 minutes the mobile phase was returned to
70% solvent B held for 3.75 minutes to re-equilibrate
the column. For 3T3-L1 cell organic phase metabolites,
the column mobile phase was held at 50% solvent B for
0.5 minutes followed by an increase from 50 to 100%
solvent B over 0.5 to 6.5 minutes. The mobile phase was
then held at 100% solvent B for 3.5 minutes. Between
10 and 10.25 minutes the mobile phase was returned to
50% solvent B held for 3.75 minutes to re-equilibrate
the column. The total ultra performance liquid chroma-
tography (UPLC) cycle was 14 minutes and the eluent
flow rate was 600 μl/minute for both methods.
Tandem mass spectrometry (MS/MS) was used for the
identification of selected lipids. Data were processed
using Micromass Markerlynx Applications Manager
(Waters Corporation).
DI-MS analysis
Mass spectrometric analysis was also performed using a
Thermo Finnigan LTQ equipped with a Finnigan Sur-
veyor pump and Finnigan Micro AS Autosampler
Thermo Finnigan, Hemel Hempstead, Hertfordshire,
UK.
The 3T3-L1 organic phase samples for DI-MS were
reconstituted in 500 μl methanol:tetrahydrofuran (2:1, v/
v). Samples were analyzed in triplicate using both posi-
tive and negative mode. The scan range was set at 100
to 1,100 m/z in profile for both positive and negative
mode. DI-MS chromatograms were processed using
Xcaliber (version 2.0; Thermo Electron). The mass data
were summed from the chromatogram for the period of
sample injection and the exact masses were exported;
t h ed a t ap o i n t sw e r es u m m e db e t w e e nMa n dM + 1 ,
normalized to total metabolite concentration and inte-
grated. Tandem mass spectrometry data were collected
for identification purposes.
13C-glucose substrate labeling study
At 2 days post-differentiation medium was removed
from the T75 flasks and replaced with DMEM (10% (v/
v) fetal bovine serum, 50 units/ml penicillin, and 50 μg/
ml streptomycin) and either 4.5 g/l unlabeled glucose
with DMSO control (n =6 ) ,1μM GW610742 (n =7 )
or 1 μM GW347845 (n =7 ) ,o r4 . 5g / l1 -
13C-glucose
with DMSO control (n =7 ) ,1μM GW610742 (n =7 )
or 1 μM GW347845 (n = 7). After 2 days cells were col-
lected and metabolites extracted as previously described.
13C-palmitate substrate labeling study
Palmitate was solubilized using a dialyzed albumin solu-
tion. At 2 days post-differentiation medium was
removed from the T75 flasks and replaced with DMEM
(serum free, 50 units/ml penicillin, and 50 μg/ml strep-
tomycin) and either 70 μM unlabeled palmitate with
DMSO control (n =6 ) ,1μM GW610742 (n =7 )o r1
μMG W 3 4 7 8 4 5( n =7 ) ,o r7 0μMU -
13C labeled palmi-
tate with DMSO control (n =6 ) ,1μM GW610742 (n =
7) or 1 μM GW347845 (n = 7). After 2 days cells were
collected and metabolites extracted as previously
described.
13C-Heteronuclear single quantum coherence NMR
Dried organic phase extracts were dissolved in 600 μlo f
deuterated chloroform. Samples were analyzed using a
DRX Avance II+ spectrometer interfaced to a 5-mm
TXI ATMA probe. Analysis was performed using two-
dimensional H-1/X correlation via double inept transfer
with sensitivity improvement. Spectral widths of 10.00
ppm and 160 ppm were used in the F2 (1H) and F1
(13C) dimensions, respectively, with an offset of 75.00
ppm. Spectra were acquired using 96 scans with a
relaxation delay of 1.0 s. Datasets were zero-filled and
multiplied by sine bell squared functions prior to Four-
ier transformation.
13C-labeled substrate GC-MS analysis
Analysis of organic and aqueous phases was carried out
as previously described above. Enrichment of metabo-
lites was identified by calculating isotope ratios of the M
and M+1 ions for the parent ion of the fragmentation
pattern in the case of
13C-glucose metabolism analysis
and TCA cycle intermediates originating from
13C-pal-
mitate oxidation. For fatty acid synthesis and desatura-
tion products from
13C-labeled palmitate an ion ratio of
M+16/M was used, and for fatty acids originating from
oxidation of
13C-labeled palmitate an ion ratio of M+n/
M was used, where n = the carbon chain length of the
fatty acid. Statistical analysis was performed using a uni-
variate Student t-test.
Multivariate analysis
Multivariate data analysis was performed using SIMCA-
P
+ 11.0 (Umetrics AB, Umeå, Sweden). NMR, DI-MS
and UPLC-MS data sets were mean-centered and Par-
eto-scaled prior to analysis. GC-MS data sets were
scaled to unit variance (UV) as only manually fitted
peaks were analyzed. Data sets were analyzed using
principal components analysis and PLS-DA. Metabolite
changes responsible for clustering or regression trends
within the pattern recognition models were identified by
interrogating the corresponding loadings plot. Metabo-
lites identified in the variable importance in projections/
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if they contributed to separation in the models with a
confidence limit of 95%.
Respirometric analysis of PPARδ and PPARg agonist-
treated 3T3-L1 cells
Cells were grown, treated with either vehicle control, the
PPARδ agonist or the PPARg agonist for 2 days prior to
collection into respiration medium (100 mM KCl, 50
mM MOPS (3-(N-morpholino)propanesulfonic acid), 1.0
mM KH2PO4, 1.0 mg/ml defatted bovine serum albu-
min, pH 7.4). Respiratory rates of in situ permeabilized
3T3-L1 cells were measured using a Clark-type oxygen
electrode (Strathkelvin Instruments Ltd, Glasgow, UK)
[36]. Respiration rates were recorded and quantified
using 782 Oxygen System v3.0 software (Strathkelvin
Instruments). Oxygen concentrations were measured
continuously in 0.5 ml respiration medium containing
250,000 cells in a respiration chamber maintained at 37°
C for 40 minutes. The cells were initially permeabilized
with the addition of Digitonin (25 μg/ml), before malate
(5 mM) plus palmitoyl-carnitine (0.04 mM) were added
as respiratory substrates to measure the fatty acid oxida-
tion rates. Respiration was stimulated by the addition of
a saturating concentration of ADP (2 mM) plus MgCl2
(0.6 mM) and subsequently measured. Antimycin (5
μM) was then added to inhibit complex III of the elec-
tron transport chain, and respiration ceased. Complex
IV respiration was stimulated by addition of the artificial
substrates TMPD (N, N, N’,N ’-tetramethyl-p-phenyle-
nediamine dihydrochloride, 0.5 mM) and ascorbate (2
mM). Finally, respiration was terminated by addition of
the complex IV inhibitor sodium azide (3 mM).
Microarray analysis of PPARδ agonist-treated 3T3-L1 cells
3T3-L1 adipocytes were cultured and then treated with
either the PPARδ agonist, the PPARg agonist or vehicle
control as described above (n = 6 independent indivi-
dual hybridizations for each treatment group). RNA was
extracted using RNeasy (Qiagen GmbH, Hilden, Ger-
many). Approximately 5 mg of cells was used per sam-
ple for RNA isolation. Procedures were carried out
according to the manufacturer’s instructions. Extracted
RNA was quantified and its purity assessed using a
Nanodrop ND-1000 Spectrometer (Nanodrop Technolo-
gies Inc., Wilmington, NC, USA) to measure the absor-
bance at 260 nm and the A260/A280 ratio, respectively.
Illumina Infinium Gene Expression BeadArrays (Illu-
mina Inc., San Diego, CA, USA) were used to perform
transcriptomics. A mouse WG6 array platform was used
with 45,281 probes. Analysis was performed with R/Bio-
Conductor version 2.5. The R package lumi [37] was
used with the detection P-value threshold set to 0.01.
Probes were required to be successfully detected (P-
value < 0.01 in Lumi) in at least one sample to pass the
selection. The data were transformed using variance sta-
bilization [38] and then normalized using quantile nor-
malization. Gene expression was compared using the R
package limma [39] with a 95% confidence interval. The
selected and normalized data were then analyzed using
Simca-P+. The 6% of transcripts most responsible for
separation in the multivariate models were then exam-
ined (3% most increased and 3% most decreased in trea-
ted cells as identified in the multivariate models). The
microarray data have been deposited with the Gene
Expression Omnibus and have the accession number
[GSE26207].
The Reactome Skypainter tool was used to determine
which pathways were statistically significant in terms of
key perturbations [13]. From a given set of genes parti-
cipating in a pathway, the total genes for Mus musculus
and the submitted genes (genes increased in PPARδ-o r
PPARg-activated cells) of which N genes participate in a
pathway, the probability of observing at least N genes
from a pathway if that pathway is not overrepresented
in the submitted list of genes is calculated using Fisher’s
exact test. A P-value smaller than the significance level
suggests the pathway is significantly represented.
Univariate statistical analysis methodology
Univariate analysis was performed using an unpaired
Student’s t-test with a significance level set to P <0 . 0 5 .
An F-test was also utilized to compare the variance of
two distributions. All univariate analysis was conducted
in GraphPad Prism (version 4).
Additional material
Additional file 1: Figure S1 - M+1/M isotope ratio
13C enrichment of
lactate, succinate, glutamate and arachidate. (a-c) M+1/M isotope
ratio
13C enrichment of (a) lactate, (b) succinate and (c) glutamate
analyzed by GC-MS of the aqueous fraction from control and PPARg
agonist-treated 3T3-L1 cells incubated with 1-
13C-glucose. (d) M+1/M
isotope ratio
13C enrichment of arachidate analyzed by GC-MS of the
organic fraction from control and PPARg agonist-treated 3T3-L1 cells
incubated with 1-
13C-glucose. *P < 0.05. The metabolites have been
mapped to the glycolysis, TCA cycle and fatty acid synthesis metabolic
pathways. An upward pointing arrows indicates a metabolite increased
in
13C enrichment by PPARg activation, and a downward pointing arrows
indicates a metabolite decreased in
13C enrichment by PPARg activation.
Parent ions were used to calculate ion ratio.
Additional file 2: Figure S2 - the average integrated area of the
two-dimensional HSQC-NMR organic fraction glycerol peak. (a) A
graph of the average integrated area of the two-dimensional HSQC-NMR
organic fraction glycerol peak (
13C chemical shift 62.04) from control and
1 μM PPARδ agonist-treated 3T3-L1 adipocytes incubated in 1-
13C
glucose. (b) A graph of the average integrated area of the two-
dimensional HSQC-NMR organic fraction glycerol peak (
13C chemical shift
62.17) from control and 1 μM PPARδ agonist-treated 3T3-L1 adipocytes
incubated in 1-
13C glucose. (c) A graph of the average integrated area of
the two-dimensional HSQC-NMR organic fraction esterified glycerol peak
from control and 1 μM PPARδ agonist-treated 3T3-L1 adipocytes
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13C glucose. *P < 0.05, ***P < 0.005. Parent ions were
used to calculate ion ratio.
Additional file 3: Figure S3 - M+1/M isotope ratios. (a, b) The M+1/M
isotope ratio
13C enrichment of (a) glutamate and (b) isocitrate analyzed
by GC-MS of the aqueous fraction from control and PPARg agonist-
treated 3T3-L1 cells incubated with
13C-U-palmitate. (c-e) Graphs
showing the isotope ratio
13C enrichment of myristate (c), arachidate (d)
and palmitate (e) analyzed by GC-MS of the organic fraction from control
and PPARg agonist-treated 3T3-L1 cells incubated with
13C-U-palmitate.
The metabolites have been mapped to the TCA cycle and fatty acid b-
oxidation/synthesis metabolic pathways. Red indicates a metabolite
increased in
13C enrichment by PPARg activation. Blue indicates a
metabolite decreased in
13C enrichment by PPARg activation. *P < 0.05,
**P < 0.01,***P < 0.005. Parent ions were used to calculate ion ratio.
Additional file 4: Figure S4 - the effect of PPARg activation on the
integration of the energy metabolism pathways of 3T3-L1
adipocytes. A diagram showing the effect of PPARg activation on the
integration of the energy metabolism pathways of 3T3-L1 adipocytes
based on the combination of results from the metabolomic,
transcriptomic and stable isotope labeling studies. Red indicates an
increase in concentration or expression in cells treated with the PPARg
selective agonist GW347845. Blue indicates a decrease in concentration
in cells treated with the PPARg selective agonist GW347845.
Abbreviations
BCAA: branched chain amino acid; CoA: coenzyme A; DI: direct infusion;
DMEM: Dulbecco’s modified Eagles media; FBS: fetal bovine serum; GC: gas
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